Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Anna C Renner

Showing results (11-20 of 31) with videos related to

Pageof 4
Sort By:
ACS Medicinal Chemistry Letters|December 17, 2025
Engineering the Next Generation of Psychedelic Therapeutics through Serotonergic Precision and Pharmacokinetic ControlAnna C Renner, Robert B Kargbo
ACS Medicinal Chemistry Letters|March 18, 2026
Emerging Paradigms in Immune-Focused Drug DiscoveryAnna C Renner, Robert B Kargbo
ACS Medicinal Chemistry Letters|March 18, 2026
Modulation of Cancer Networks through Protein Degradation, DNA Repair Inhibition, and Quantitative InteractomicsAnna C Renner, Robert B Kargbo
ACS Medicinal Chemistry Letters|January 14, 2026
Multidimensional Strategies in Oncology: From Macrocyclic Kinase Inhibitors to Physicochemical and Transcriptomic DiagnosticsAnna C Renner, Robert B Kargbo
ACS Medicinal Chemistry Letters|January 14, 2026
Molecular Diagnostics, Circuit-Calming Modulators, and Controlled Neuroplastogens: Emerging Strategies in Precision Neuropsychiatric TherapeuticsAnna C Renner, Robert B Kargbo
ACS Medicinal Chemistry Letters|December 17, 2025
Dual Innovations in EGFR Degradation and Antigen-Specific Modulation for Multiple SclerosisAnna C Renner, Robert B Kargbo
ACS Medicinal Chemistry Letters|November 19, 2025
Toward Precision Psychedelic Therapies: Chemical, Computational, and Neuromodulatory InnovationsAnna C Renner, Robert B Kargbo
ACS Medicinal Chemistry Letters|January 14, 2026
Advances in Psychedelic Therapeutics: Multimodal Iboga Analogs, EEG-Guided Psilocybin Dosing, and Optimized Harmine-DMT FormulationsAnna C Renner, Robert B Kargbo
ACS Medicinal Chemistry Letters|November 19, 2025
LRRK2 Degraders for Parkinson's Disease and Inflammation: Tau and α‑Synuclein Degraders for NeurodegenerationAnna C Renner, Robert B Kargbo
ACS Medicinal Chemistry Letters|February 18, 2026
Multimodal Modulation of the IL-17 Axis: Integrating Small-Molecule Inhibition, PEGylation, and Targeted Nanoparticle ImmunotherapyAnna C Renner, Robert B Kargbo
Pageof 4

Showing results (11-20 of 31) with videos related to

Sort By:
Pageof 4
ACS Medicinal Chemistry Letters|December 17, 2025
Engineering the Next Generation of Psychedelic Therapeutics through Serotonergic Precision and Pharmacokinetic ControlAnna C Renner, Robert B Kargbo
ACS Medicinal Chemistry Letters|March 18, 2026
Emerging Paradigms in Immune-Focused Drug DiscoveryAnna C Renner, Robert B Kargbo
ACS Medicinal Chemistry Letters|March 18, 2026
Modulation of Cancer Networks through Protein Degradation, DNA Repair Inhibition, and Quantitative InteractomicsAnna C Renner, Robert B Kargbo
ACS Medicinal Chemistry Letters|January 14, 2026
Multidimensional Strategies in Oncology: From Macrocyclic Kinase Inhibitors to Physicochemical and Transcriptomic DiagnosticsAnna C Renner, Robert B Kargbo
ACS Medicinal Chemistry Letters|January 14, 2026
Molecular Diagnostics, Circuit-Calming Modulators, and Controlled Neuroplastogens: Emerging Strategies in Precision Neuropsychiatric TherapeuticsAnna C Renner, Robert B Kargbo
ACS Medicinal Chemistry Letters|December 17, 2025
Dual Innovations in EGFR Degradation and Antigen-Specific Modulation for Multiple SclerosisAnna C Renner, Robert B Kargbo
ACS Medicinal Chemistry Letters|November 19, 2025
Toward Precision Psychedelic Therapies: Chemical, Computational, and Neuromodulatory InnovationsAnna C Renner, Robert B Kargbo
ACS Medicinal Chemistry Letters|January 14, 2026
Advances in Psychedelic Therapeutics: Multimodal Iboga Analogs, EEG-Guided Psilocybin Dosing, and Optimized Harmine-DMT FormulationsAnna C Renner, Robert B Kargbo
ACS Medicinal Chemistry Letters|November 19, 2025
LRRK2 Degraders for Parkinson's Disease and Inflammation: Tau and α‑Synuclein Degraders for NeurodegenerationAnna C Renner, Robert B Kargbo
ACS Medicinal Chemistry Letters|February 18, 2026
Multimodal Modulation of the IL-17 Axis: Integrating Small-Molecule Inhibition, PEGylation, and Targeted Nanoparticle ImmunotherapyAnna C Renner, Robert B Kargbo
Pageof 4